A bruised Eli Lilly buys rights to Centrexion's early-stage pain drug for $47.5M upfront
Eli Lilly is working on putting its woes in the rearview mirror. In recent months, a late-stage failure triggered the withdrawal of its cancer drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
